Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Lechleiter takes up Big Pharma's torch to 'debunk' negative myths

Eli Lilly & Co. CEO John Lechleiter is trying to debunk the "Five Big Myths" about Big Pharma. In a Forbes column, Lechleiter takes on the claim that R&D spending is exaggerated to justify high prices--plus four more.

J&J nears $7.5M deal in Risperdal case that could have cost $1.2B

It took three years of legal wrangling by Johnson & Johnson, but for this kind of reprieve, it was time well spent. The company agreed to pay $7.5 million to wrap up a notorious Arkansas state lawsuit over Risperdal--a tiny fraction of the original $1.2 billion trial verdict.

Hep C patient sues Blue Cross for blocking access to Harvoni

A patient denied the latest hepatitis C drugs has sued her insurance company. In this case, it's Anthem Blue Cross, and the California plaintiff says her plan blocked her from treatment because she's not sick enough to qualify under its rules.

FDA's SGLT2 warning bad news for AZ, J&J and Lilly--but could be a boon for Merck

Top companies are counting on the SGLT2 class of diabetes meds to ratchet up sales. But a new FDA warning could put a crimp on that plan.

Early ASCO winners? Roche and Pfizer, and to a lesser extent, BMS

The curtain is up on the first act of the annual cancer drug lollapalooza at ASCO. The first round of abstracts spotlights a series of early winners--including Roche--and at least one big loser: Puma Biotechnology.

Here's a lucrative idea: Turn a drug into an orphan med, reap 6 months extra exclusivity

Would-be makers of rare disease meds, rejoice: A 6-month exclusivity extension, proposed last year in Congress, has returned. The 21st Century Cures Act, now under consideration in the House of Representatives, once again includes a measure that would prolong competition-free marketing for some meds repurposed to treat rare diseases.

UPDATED: Pfizer gets friendly backing in appeal over blind rep's bid for paid driver

In the department of employee lawsuits, Pfizer is the latest drugmaker in the hot seat. But the seat is hotter for the visually impaired sales rep who sued because the company wouldn't provide a driver to ferry her to doctors' offices.

Big Pharma's a C student, rep study finds, with Bayer at the top, Novartis at bottom

When it comes to Big Pharma's reputation, "average" says it all. That's the story from the research firm Reputation Institute, which perennially puts major drugmakers right smack in the middle of its scorecard. In other words, pharma is a C student.

Ranks of 'super-spender' patients triple, pushing drug bills up $52B

A small but growing number of patients is racking up big drug bills in the U.S. On a per-patient basis, it's staggering: Some 576,000 Americans generated more than $50,000 in prescription drug costs each last year, according to a report from Express Scripts. And nearly 140,000 of them totted up drug bills of $100,000 or more.

Endo plots a double-sized salesforce, new DTC push for Stendra relaunch

Not satisfied with the way its new purchase Auxilium had handled Stendra marketing, Endo plans to relaunch the erectile dysfunction med, which it sells in partnership with Vivus. Endo is doubling the size of the Stendra salesforce, rolling out a new DTC effort, and keeping a close eye on inventory levels, which had built up too much for its taste.